Suzhou GrandKol Pharm Technology

GrandKol Pharm is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to the discovery of innovative small molecule drugs. The company utilizes a specialized platform that combines fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) to address challenging targets, including protein-protein interactions and previously undruggable proteins. Its research and development efforts are primarily focused on the fields of oncology and immunology, with a robust pipeline targeting the RAS/MAPK signaling pathway. The lead program, GK-001, is a potent SHP2 inhibitor currently in Phase 1 clinical trials for the treatment of solid tumors. GrandKol aims to leverage its structural biology expertise to develop high-quality precision medicines for global patients.